Αποτελέσματα Αναζήτησης
24 Αυγ 2015 · This article reviews the clinical problem of hyperkalemia and identifies predictors of hyperkalemia in patients with hypertension, CKD, diabetes mellitus, and heart failure.
23 Οκτ 2019 · Hyperkalemia (serum potassium [K +] >5.0 or >5.5 mEq/L) is a potentially life-threatening complication of chronic kidney disease (CKD).
For this review, we identified 15 studies comparing different potassium binders approaches for patients with CKD, and the information from these studies is of insufficient certainty to inform clinical care or policy.
The KBindER (K + Binders in Emergency Room and hospitalized patients) clinical trial is the first head-to-head evaluation of oral potassium binders (cation-exchange resins) for acute hyperkalemia therapy.
Potassium-binding drugs reduce serum Kþ levels via ion ex-change mechanisms in the gastrointestinal tract. Sodium zirco-nium cyclosilicate is a nonpolymer compound that exchanges Kþ for sodium and hydrogen ions. In contrast, patiromer is a polymer that exchanges Kþ for calcium ions.
5 Απρ 2023 · Background: The KBindER (K + Binders in Emergency Room and hospitalized patients) clinical trial is the first head-to-head evaluation of oral potassium binders (cation-exchange resins) for acute hyperkalemia therapy.
16 Φεβ 2023 · Potassium binders are medications that help lower high potassium levels. They attach (bind) extra potassium in your body to the stool (poop) in your intestines, which prevents some extra potassium from entering your blood. The excess potassium then leaves your body when you go to the bathroom.
